Richard Simon Machado

Richard Simon Machado

Auto-generated profile, based on publicly available information

Richard Simon Machado

Laboratory of Neurobiology of Inflammatory and Metabolic Processes, Graduate Program in Health Sciences, Health Sciences Unit, University of South Santa Catarina, Tubarão, SC, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Experimental Gerontology
Verified
Journal Article
Closed access
WMWillian Margotti
Willian Margotti
MGMariana Pereira de Souza Goldim
Mariana Pereira de Souza Goldim
RMRichard Simon Machado
Richard Simon Machado
EBErick Bagio
Erick Bagio
CDCarlos Dacoregio
Carlos Dacoregio
FPFabricia Petronilho
Fabricia Petronilho

13 November 2024 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
SBSandra Bonfante
Sandra Bonfante
MNMartins Back Netto
Martins Back Netto
AJAloir Neri de Oliveira Junior
Aloir Neri de Oliveira Junior
KMKhiany Mathias
Khiany Mathias
RMRichard Simon Machado
Richard Simon Machado
FPFabricia Petronilho
Fabricia Petronilho

25 October 2021 in Developmental Neuroscience
Verified
Journal Article
Closed access
PDF file
NRNaiana da Rosa
Naiana da Rosa
FMFabiana Durante de Medeiros
Fabiana Durante de Medeiros
JOJuliana de Oliveira
Juliana de Oliveira
ALAna Olívia Martins Laurentino
Ana Olívia Martins Laurentino
EPEduardo de Medeiros Peretti
Eduardo de Medeiros Peretti
FPFabrícia Petronilho
Fabrícia Petronilho
6-Shogaol is one of the main active phenolic components of ginger and has neuroprotective effects by protecting brain against the oxidative stress and regulate the levels of neurotrophic factors. The objective of the present study was to verify the effect of 6-shogaol on neurochemical parameters in offspring after maternal immune activation by lipopolysaccharide (LPS) in rats. Twelve pregnant Wistar rats received 100 μg/kg of LPS or saline solution on the gestational day 9.5. Male offspring participated in the study and from the postnatal days (PND) 30 and 55, respectively, they were supplemented with 6-shogaol or saline solution, by gavage at a dose of 10 mg/kg/day, orally for 5 days. In PND 37 and 62, analysis of kinase signaling regulated by extracellular signal 1/2 (ERK 1/2), levels of neurotrophic factor derived from the brain (BDNF), and neuron-specific enolase (NSE), lipid and protein oxidative damage was evaluated by 4-hydroxy-2-nonenal (HNE) and 3-nitrotyrosine (3-NT), respectively, and myeloperoxidase (MPO) activity was performed in the hippocampus. Prenatal exposure to LPS significantly decreased ERK and BDNF levels in PND 37 and 62, increased NSE levels and lipid damage in rats in PND 37, and increased 3-NT level in rats in PND 62. With treatment using 6-shogaol, an increase in ERK and BDNF levels was identified in PND 37 and 62 and a reduction in HNE and MPO activity in rats in PND 37 and 62, respectively. 6-Shogaol positively increased markers of neuronal growth, plasticity and synaptic activity and reduced oxidative damage in the hippocampus in an animal model of autism by maternal immune activation.

9 November 2021 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
PDF file
NRNaiana da Rosa
Naiana da Rosa
FMFabiana Durante de Medeiros
Fabiana Durante de Medeiros
JOJuliana de Oliveira
Juliana de Oliveira
ALAna Olívia Martins Laurentino
Ana Olívia Martins Laurentino
EPEduardo de Medeiros Peretti
Eduardo de Medeiros Peretti
FPFabrícia Petronilho
Fabrícia Petronilho

2 November 2022 in Neuroimmunomodulation
Verified
Journal Article
Closed access
PDF file
LJLarissa Joaquim
Larissa Joaquim
AGAmanda Della Giustina
Amanda Della Giustina
RMRichard Simon Machado
Richard Simon Machado
KMKiuanne Lino Lobo Metzker
Kiuanne Lino Lobo Metzker
SBSandra Bonfante
Sandra Bonfante
FPFabricia Petronilho
Fabricia Petronilho
Many coronavirus disease 2019 (COVID-19)-recovered patients report signs and symptoms and are experiencing neurological, psychiatric, and cognitive problems. However, the exact prevalence and outcome of cognitive sequelae is unclear. Even though the severe acute respiratory syndrome coronavirus 2 has target brain cells through binding to angiotensin-converting enzyme 2 (ACE2) receptor in acute infection, several studies indicate the absence of the virus in the brain of many COVID-19 patients who developed neurological disorders. Thus, the COVID-19 mechanisms for stimulating cognitive dysfunction may include neuroinflammation, which is mediated by a sustained systemic inflammation, a disrupted brain barrier, and severe glial reactiveness, especially within the limbic system. This review explores the interplay of infected lungs and brain in COVID-19 and its impact on the cognitive function.

1 February 2025 in Cannabis & Cannabinoid Research
Verified
Journal Article
Closed access
SSSolange de Souza Stork
Solange de Souza Stork
KMKhiany Mathias
Khiany Mathias
DSDavid dos Santos
David dos Santos
FLFabrício Weinheimer Lippert
Fabrício Weinheimer Lippert
RMRichard Simon Machado
Richard Simon Machado
FPFabricia Petronilho
Fabricia Petronilho
Introduction: Cannabinoids are increasingly being explored as a potential treatment for neurodegenerative diseases. This article aims to provide a narrative review of available data on the treatment of neurological disorders with cannabis constituents, focusing on ischemic stroke. Methods: Selected articles are summarized to describe design, results, limitations, conclusions, and implications about this theme. Results: The growing understanding of the endocannabinoid system and the cannabinoid receptors distribution in all human body systems and organs and particularly in brain structures importantly involved in myelination processes, suggests potential benefits for stroke symptoms and overall patient improvement. However, the variety of studied compounds, the different administration routes, dosages, and timing complicates data comparison, especially due to limited studies about these compounds, peculiarly in stroke patients. Thereat, this review to showcase disparities in findings and to summarize current advancements in cannabinoid use for potential future treatments. Conclusion: This article offers a review of the current literature in the field and discuss a pragmatic approach to the clinical use of cannabinoids in patients with ischemic stroke.